Literature DB >> 10022217

Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy.

M Musi1, R G Carbone, C Bertocchi, D P Cantalupi, G Michetti, C Pugliese, G Virotta.   

Abstract

Several authors proposed the stage at diagnosis and some histopathological features as prognostic factors of bronchial carcinoids. However, since large tumour diameters or nodal metastases are frequently associated to aggressive histology, their prognostic role is unclear. To investigate the relationships between the clinicopathological parameters at diagnosis and outcome, 21 patients were analysed. Overall 26% of the radically resected patients recurred. Recurrences and disease-specific mortality were related to atypical histology and, only in cases with typical histology, to the presence of hilar or mediastinal lymph node metastases. These prognostic factors were valuable independently of the size of the primary tumour, that was remarkably homogeneous, always less than 3 cm, thus not predictive of recurrence. Moreover we evaluated the role of somatostatin receptor scintigraphy, a diagnostic tool only preliminary studied in this field. Scintigraphy with 111In-octreotide revealed the primary tumours at diagnosis (8/8), the increase in tumour size in two unresected patients, and all the cases of recurrent or metastatic disease (5/11), sometimes before the appearance of symptoms. These results suggest the usefulness of histology and nodal status as prognostic factors in clinical practice. Somatostatin receptor scintigraphy turns out to be a powerful diagnostic tool, for an accurate staging and an early diagnosis of recurrence in bronchial carcinoids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10022217     DOI: 10.1016/s0169-5002(98)00075-0

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

Review 1.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

2.  Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome.

Authors:  E Grossrubatscher; F Vignati; P Dalino; M Possa; P A Belloni; A Vanzulli; M Bramerio; A Marocchi; O Rossetti; F Zurleni; P Loli
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Authors:  Gianluca Masi; Lorenzo Fornaro; Samanta Cupini; Fotios Loupakis; Enrico Vasile; Giacomo G Baldi; Irene Stasi; Lisa Salvatore; Alfredo Falcone
Journal:  Nat Rev Clin Oncol       Date:  2009-11       Impact factor: 66.675

Review 4.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

5.  [Treatment of large cell neuroendocrine lung cancer by implantation of radioactive 125I seeds: a case report].

Authors:  Jinshuang Lv; Shude Chai; Guangjun Zheng; Weiliang Yan; Zhen Feng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.